<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917784</url>
  </required_header>
  <id_info>
    <org_study_id>DI/18/111/03/067</org_study_id>
    <nct_id>NCT03917784</nct_id>
  </id_info>
  <brief_title>Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes</brief_title>
  <official_title>Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de México Dr. Eduardo Liceaga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de México Dr. Eduardo Liceaga</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of oral supplementation with curcumin on the insulin
      sensitivity in subjects with prediabetes. The half of participants will receive curcumin and
      bioperine in combination, while the other half receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The therapeutic strategies for prediabetes to this day are based on the change of habits,
      mainly food and exercise plans. It has been advice, in specific circumstances, to grant a
      pharmacological regimen.

      Curcumin or Curcuma Longa ((1E,6E)21,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-
      heptadiene-3,5-dione), is the main ingredient of the Hindu condiment, Turmeric, which is
      obtained from the Rhizome plant. In new studies, it has been documented that the oral
      consumption of curcumin (Curcuma longa) in pre-diabetic and diabetic patients has a positive
      effect as an antidiabetic agent thanks to its anti-inflammatory, antioxidant, antithrombotic,
      cardio and neuroprotective effects. In animal models, it has been shown that oral curcumin
      consumption is capable of increasing insulin sensitivity in liver, muscle and adipose tissue,
      increases glucose uptake in muscle and insulin secretion, which is reflected in the reduction
      of hyperglycemia, glycosylated hemoglobin, decrease of the homeostatic model assessment of
      insulin resistance (HOMA-IR) and decrease of serum lipids.

      Curcumin has been included in the oriental diet since ancient times and is used in
      traditional medicine, which is why it is considered safe, since its consumption is approved
      by the FDA (Federal Drugs Administration). A 12g per day dose has shown no side effects in
      humans. Therefore, it is proposed that the consumption of curcumin in pre-diabetic patients
      can improve glucose tolerance and decrease insulin resistance parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled clinical trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA- IR</measure>
    <time_frame>3 months</time_frame>
    <description>(Insulin µU/ml)(Glucose mg/dl)/405.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA- Beta</measure>
    <time_frame>3 months</time_frame>
    <description>(20)(FPI)/(FPG - 3.5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matsuda index</measure>
    <time_frame>3 months</time_frame>
    <description>10,000/√[(basal glucose)(basal insulin)*(glucose)(insulin)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>height</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>height in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>waist circumference in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hip circumference.</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>hip circumference in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>insulin in µU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>triglycerides in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholesterol</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>cholesterol in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>HDL cholesterol in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>LDL cholesterol in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>uric acid</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>uric acid in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>creatinine in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urea</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>urea in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine amino transferase</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>alanine amino transferase in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alkaline phosphatase</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>alkaline phosphatase in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactic dehydrogenase</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>lactic dehydrogenase in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycosylated hemoglobin</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>glycosylated hemoglobin in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total bilirubin</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>total bilirubin in mg/dl</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Curcumin and bioperine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive curcumin 500 mg and bioperine 5 mg oral dosing every 12 hours for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive placebo (starch) 500 mg oral dosing every 12 hours for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Oral supplementation with curcumin 500 mg oral dosing for 3 months</description>
    <arm_group_label>Curcumin and bioperine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Starch</intervention_name>
    <description>Oral supplementation with starch 500 mg oral dosing for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women with age between 18 and 60 years old.

          -  With prediabetes diagnosis, according to the American Diabetes Association :

               1. Fasting serum glucose: 100-125 mg/dL

               2. Glycosylated hemoglobin (HbA1c): 5.7-6.4%

               3. Post-prandial glucose: 140-199 mg/dL after an oral dose of 75 g of glucose.

        Exclusion Criteria:

          -  Subjects with any type of diabetes.

          -  Subjects with body mass index &gt; 35 kg/m2

          -  Pregnant Women.

          -  Volunteers who ingest drugs that alter blood glucose levels, antiplatelet agents,
             angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists,
             fibrates, statins.

          -  Subjects with serum creatinine &gt; 2 mg/dL or in renal replacement therapy.

          -  Subjects that normally consume food supplements.

          -  Subjects with acute infections or with chronical diseases (cancer, rheumatoid
             arthritis, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>César L González</last_name>
    <phone>01 993 117 1322</phone>
    <email>celsbca_21033@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General de México Dr. Eduardo Liceaga</name>
      <address>
        <city>Mexico City</city>
        <state>Cuauhtémoc</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Roldan</last_name>
      <phone>2789-2000</phone>
      <phone_ext>1164</phone_ext>
      <email>ernest.roldan@usa.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>American Diabetes Association. 5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S51-S54. doi: 10.2337/dc18-S005. Review.</citation>
    <PMID>29222376</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. doi: 10.2337/dc18-S002. Review.</citation>
    <PMID>29222373</PMID>
  </reference>
  <reference>
    <citation>Alibasic E, Ramic E, Alic A. Prevention of diabetes in family medicine. Mater Sociomed. 2013;25(2):80-2. doi: 10.5455/msm.2013.25.80-82.</citation>
    <PMID>24082827</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E. Definition of intervention points in prediabetes. Lancet Diabetes Endocrinol. 2014 Aug;2(8):667-75. doi: 10.1016/S2213-8587(13)70175-X. Epub 2014 Jan 28.</citation>
    <PMID>24731662</PMID>
  </reference>
  <results_reference>
    <citation>Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA, Zárate-Rojas E, Villalpando S, Barrientos-Gutiérrez T. [Prevalence of previously diagnosed diabetes mellitus in Mexico.]. Salud Publica Mex. 2018 May-Jun;60(3):224-232. doi: 10.21149/8566. Spanish.</citation>
    <PMID>29746739</PMID>
  </results_reference>
  <results_reference>
    <citation>Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A; ACT NOW Study. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013 Nov;36(11):3607-12. doi: 10.2337/dc13-0520. Epub 2013 Sep 23.</citation>
    <PMID>24062330</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdul-Ghani MA, Abdul-Ghani T, Stern MP, Karavic J, Tuomi T, Bo I, Defronzo RA, Groop L. Two-step approach for the prediction of future type 2 diabetes risk. Diabetes Care. 2011 Sep;34(9):2108-12. doi: 10.2337/dc10-2201. Epub 2011 Jul 25.</citation>
    <PMID>21788628</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamy A, Tong W, Jung H, Gafni A, Singh K, Tyrwhitt J, Yusuf S, Gerstein HC; ORIGIN Investigators. Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial. J Diabetes Complications. 2014 Jul-Aug;28(4):553-8. doi: 10.1016/j.jdiacomp.2014.02.012. Epub 2014 Mar 2.</citation>
    <PMID>24684774</PMID>
  </results_reference>
  <results_reference>
    <citation>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.</citation>
    <PMID>3899825</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000 Jan;23(1):57-63.</citation>
    <PMID>10857969</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep;22(9):1462-70.</citation>
    <PMID>10480510</PMID>
  </results_reference>
  <results_reference>
    <citation>Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012 Nov;35(11):2121-7. doi: 10.2337/dc12-0116. Epub 2012 Jul 6.</citation>
    <PMID>22773702</PMID>
  </results_reference>
  <results_reference>
    <citation>Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, Li XX, Sun CH. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res. 2013 Sep;57(9):1569-77. doi: 10.1002/mnfr.201200131. Epub 2012 Aug 29.</citation>
    <PMID>22930403</PMID>
  </results_reference>
  <results_reference>
    <citation>Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem. 2014 Feb;25(2):144-50. doi: 10.1016/j.jnutbio.2013.09.013. Epub 2013 Nov 6.</citation>
    <PMID>24445038</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao SG, Li Q, Liu ZX, Wang JJ, Wang XX, Qin M, Wen QS. Curcumin attenuates insulin resistance in hepatocytes by inducing Nrf2 nuclear translocation. Hepatogastroenterology. 2011 Nov-Dec;58(112):2106-11. doi: 10.5754/hge11219.</citation>
    <PMID>22024084</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang C, Kim E. Synergistic effect of curcumin and insulin on muscle cell glucose metabolism. Food Chem Toxicol. 2010 Aug-Sep;48(8-9):2366-73. doi: 10.1016/j.fct.2010.05.073. Epub 2010 Jun 1.</citation>
    <PMID>20561944</PMID>
  </results_reference>
  <results_reference>
    <citation>Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W, Lu H, Fantus IG, Jin T. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One. 2012;7(1):e28784. doi: 10.1371/journal.pone.0028784. Epub 2012 Jan 9.</citation>
    <PMID>22253696</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdel Aziz MT, El-Asmar MF, El Nadi EG, Wassef MA, Ahmed HH, Rashed LA, Obaia EM, Sabry D, Hassouna AA, Abdel Aziz AT. The effect of curcumin on insulin release in rat-isolated pancreatic islets. Angiology. 2010 Aug;61(6):557-66. doi: 10.1177/0003319709356424. Epub 2010 Apr 14.</citation>
    <PMID>20395228</PMID>
  </results_reference>
  <results_reference>
    <citation>Aziz MT, El-Asmar MF, Rezq AM, Wassef MA, Fouad H, Roshdy NK, Ahmed HH, Rashed LA, Sabry D, Taha FM, Hassouna A. Effects of a novel curcumin derivative on insulin synthesis and secretion in streptozotocin-treated rat pancreatic islets in vitro. Chin Med. 2014 Jan 14;9(1):3. doi: 10.1186/1749-8546-9-3.</citation>
    <PMID>24422903</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu GX, Lin H, Lian QQ, Zhou SH, Guo J, Zhou HY, Chu Y, Ge RS. Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats. PLoS One. 2013;8(3):e49976. doi: 10.1371/journal.pone.0049976. Epub 2013 Mar 22.</citation>
    <PMID>23533564</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagabhushan M, Bhide SV. Curcumin as an inhibitor of cancer. J Am Coll Nutr. 1992 Apr;11(2):192-8.</citation>
    <PMID>1578097</PMID>
  </results_reference>
  <results_reference>
    <citation>Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer. 1992;17(1):77-83.</citation>
    <PMID>1574446</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 1994 Nov 15;54(22):5841-7.</citation>
    <PMID>7954412</PMID>
  </results_reference>
  <results_reference>
    <citation>Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res. 2013 Mar;27(3):374-9. doi: 10.1002/ptr.4715. Epub 2012 May 21.</citation>
    <PMID>22610853</PMID>
  </results_reference>
  <results_reference>
    <citation>Ganjali S, Sahebkar A, Mahdipour E, Jamialahmadi K, Torabi S, Akhlaghi S, Ferns G, Parizadeh SM, Ghayour-Mobarhan M. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. ScientificWorldJournal. 2014 Feb 11;2014:898361. doi: 10.1155/2014/898361. eCollection 2014.</citation>
    <PMID>24678280</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 7, 2019</study_first_submitted>
  <study_first_submitted_qc>April 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>April 13, 2019</last_update_submitted>
  <last_update_submitted_qc>April 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de México Dr. Eduardo Liceaga</investigator_affiliation>
    <investigator_full_name>César Leonardo González Aguilar</investigator_full_name>
    <investigator_title>Internal Medicine Resident</investigator_title>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>HOMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Identified individual participant data for all primary and secondary outcomes measures will be made avaliable</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be avaliable whithin 6 months of study completion</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03917784/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

